Effect of different doses of methylprednisolone on refractory Mycoplasma pneumoniae pneumonia in children

Objective To investigate the therapeutic effect of different doses of methylprednisolone on refractory Mycoplasma pneumoniae pneumonia in children. Methods Total 120 children diagnosed as refractory Mycoplasma pneumoniae pneumonia in children's Hospital of Fuyang City from January 2018 to December 2018 were selected as the study object. They were divided into small dose group, medium dose group and large dose group according to the dose, 40 cases in each group. Each group was treated with azithromycin, and corresponding symptomatic support treatment was given, such as antipyretic, cough, phlegm, etc. On this basis, methylprednisolone was given 2 mg/(kg·d) in the low dose group, 5 mg/(kg·d) in the medium dose group, 10 mg/(kg·d) in the high dose group, once a day by intravenous drip. The total efficiency, normal time of body temperature recovery, cough improvement time, time of absence of lungs, time of hospitalization, improvement of chest film, index of inflammatory reaction and occurrence of adverse reactions were compared among the three groups. Results The total effective rate of the large dose group was higher than that of the medium dose group and the small dose group. The time of heat retreat, loss of cough, loss of lung voice, time of hospitalization, of the large dose group were significantly shorter than those in the medium dose group and the small dose group. The absorption rate of lung lesions in the large dose group was significantly higher than that in the medium dose group and the small dose group. After treatment, the C-reactive protein (CRP), IL-6, IL-10, and TNF-α were reexamined. The large dose group was the lowest, followed by the middle dose group and the low dose group. There was no statistically significant difference in adverse reactions among the three groups (P>0.05). Conclusion The treatment of refractory Mycoplasma pneumoniae pneumonia in children with large dose of methylprednisolone can significantly improve symptoms, improve curative effect, and have low adverse reaction and high safety factor, which is worthy of clinical promotion.